Health Care·Biotechnology·$11.8B
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-1.34 | N/A | N/A |
| Revenue | N/A | N/A | N/A |
management commentary, guidance changes, and full analysis available with Pro.
| EPS | $-1.34 | N/A | N/A |
| Revenue | N/A | N/A | N/A |
Tone: Neutral
Management emphasized their commitment to advancing their clinical programs. They did not provide specific financial guidance for the upcoming quarters.
Management did not provide specific guidance for future quarters.
The focus remains on ongoing clinical trials and research developments.
Madrigal Pharmaceuticals did not provide detailed revenue figures or earnings expectations, but the stock rose by 5.33% following the earnings report. This increase may reflect investor optimism about the company's ongoing clinical trials and research efforts, despite the lack of specific guidance.
AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.
No charge today · Auto-bills $8/mo after 7 days · Cancel anytime
WOODWARD INC
Nov 14, 2016